Podcasts about nobel laureates

Our analysts Seth Carpenter and Serena Tang discuss why they believe the global economy is set to slow meaningfully in the second half of 2025.Read more insights from Morgan Stanley.----- Transcript -----Serena: Welcome to Thoughts on the Market. I'm Serena Tang, Morgan Stanley's, Chief Global Cross-Asset Strategist.Seth: And I'm Seth Carpenter, Morgan Stanley's Global Chief Economist.Serena: Today we'll discuss Morgan Stanley's midyear outlook for the global economy and markets.It's Wednesday, May 21st at 10am in New York.Seth, you published a year ahead outlook last November. Since President Trump took office back in January, there's been pretty significant policy and economic uncertainty and quite a few surprises. With this in mind, what is your current outlook for the global economy for the second half of this year and into 2026.Seth: So, we titled the outlook Skewed to the Downside because we really do think the U.S. economy, the global economy, is set to slow meaningfully from where we were coming into this year. Let's start with the U.S.As you said, policy changes came in a lot this year since the new administration took over. I would say the two key ones from a macro perspective so far have been trade policy and immigration policy.Tariffs have gone up, tariffs have gone down, tariffs have been suspended. Right now, what we think is going to ultimately take place is that we will see persistent, notable tariffs on China, lower tariffs on the rest of the world, and then we'll have to see how things evolve. What does that mean? Well, it means for the U.S. higher inflation and lower growth. In addition, immigration reform means that growth is going to slow because the growth rate of the labor force is going to slow.Now around the rest of the world, the tariff shock matters as well. When the U.S. puts in tariffs on its imports from other countries, that's negative demand for those other countries. So, we're looking for pretty weak growth in the euro area. Now, I will note, lots of people were excited about possible expansionary fiscal policy in Germany, and we think that's still there. We just don't think it's enough to give the euro area robust growth.In Asia, China's a main driver of the economy. China is a big recipient of these tariffs. We think the deflation cycle that we expected in China keeps going on. This reduction in demand from the U.S. is not going to help, but there'll probably be a little bit at the margin offsetting fiscal policy.So, what does that mean put together? Lackluster growth in China. Call it 4 percent slow growth for yet another year. Overall, the global economy should step down. Will it be a recession? That's one of the key questions that we hear from clients, but we don't think so. Not quite. Just a meaningful step downSerena: Interesting. Any particular regions that seem to be bright spots or surprises -- or perhaps have seen the biggest shift in your outlook?Seth: I guess I'd flag two potential bright spots around the world. The first is India. India has been, for us, a favorite. It will have the highest growth rate of any economy that we have in our coverage area. And because it's such a big economy, that's part of why the global economy can't lose that much steam. India has lots going for it. There are cyclical factors boosting growth in the near term. But there are also longer-term structural policy driven reasons to think that Indian growth will stay solid for the foreseeable future.I guess I'd also throw in Japan. Now its growth rate isn't going to be anywhere near the kind of growth in number terms that we're going to see from India. But this has to be taken in the context of 25 years of essentially zero growth of nominal GDP. The reflationary cycle that we think started a couple years ago remains intact, even with the tariff shock. And so, we're pretty optimistic still that Japanese reflation will continue.Serena: And to what extent are U.S. tariffs contributing to global inflationary pressures? I mean, how do you expect the Fed and other central banks to respond?Seth: The tariffs are imposed by the United States on most of the imports coming into the country, whereas other countries, maybe they have some retaliatory tariffs just against the U.S., but definitely not as broad as the U.S. That means for the U.S. tariffs are going to drive up inflation domestically and drive down growth, whereas for the rest of the world, it's mostly just a negative demand shock. So, they will be disinflationary for the rest of the world and pushing down growth.What does that mean for central banks? Well, outside of the U.S., central banks are going to see this as slowing aggregate demand, and so it's pretty clear what it is that they want to do. If they were hiking, they can stop hiking. If they were going to hold steady, they can lower rates a little bit. And if they were already lowering interest rates like the European Central Bank, well they can probably keep going with that without having to worry. And that's why we think the ECB is going to lower its policy rate to probably 1.5 percent and maybe even lower, which is below where the market is expecting things.Now for the Fed, things are much more tricky. The Fed cares about inflation, the Fed cares about U.S. growth, and both of those variables are going in the opposite direction of what they want over the rest of this forecast. Right now, inflation's too high for the Fed, and history shows that inflation goes up first with tariffs before the growth rate hits. So, the Fed's probably going to wait until the hard data show a bigger slowdown in the economy, a worsening. And the labor market. That is a bigger concern for them than the already too high inflation that is set to rise further over the rest of the year.Serena: And in your view, how does trade policy uncertainty influence business investment, particularly in export-oriented industries or in economies tightly linked to U.S. demand?Seth: Yeah. I think it has to be negative and therein lies one of the biggest challenges is just how negative. And I can't say for sure. But what we do know is that an uncertainty tends to be very negative for business investment spending decisions. If you're trying to make a decision, should I build a new factory?This is something that's going to have a long life to it, and you're going to get benefits hopefully for several years. How big are those benefits relative to the cost? Well, right now it's not at all clear, and so there's an option value to waiting.And we think that uncertainty is depressing investment decisions right now. I think it has to affect export-oriented industries. There's a lot of questions about what sort of retaliatory tariffs, other countries might impose.But it also affects domestic driven businesses because, well, they're going to have to see what their demand is. And some of the ones that are just focused on the U.S. economy are selling imported goods. So, it affects businesses across the board. Serena: Right. And how do U.S. tariff hikes spill over into emerging markets, and how might these countries buffer against these shocks?Seth: Yeah, I think there's a range of outcomes and the range is as wide as there are different countries. If you stay close to home. Take Mexico. Mexico is a big trading partner with the U.S. and early on in this whole tariff discussion, they were actually the targets of lots of tariff threats. That could have hurt them directly because there'd be less demand for their exports to the United States.Now we've got some resolution. We have the trade agreement with Canada and Mexico, and most of Mexico's exports to the U.S. are exempt under those conditions. However, the indirect effect is important as well. Mexico is very attached to the U.S. economy, and so as the U.S. economy slows because of these tariffs, the Mexican economy will slow as well.But there's also an indirect effect through currency markets, and I think this is a channel that's more broadly applicable across EM. If the Fed is going to be on hold, like we think holding interest rates higher for longer than the market might currently think, that means that EM central banks who might want to lower their policy rate to support their economy are going to be caught in a bit of a bind.They can't afford to take the risks that their currency will misbehave if they ease too much too far ahead of the Fed. And so, I think there is a little bit of a constraint for EM central banks, thinking about how much can I attend to domestic matters and how much do I have to pay attention to external matters?Serena: Now, I know forecasting economic growth is difficult in even the best of times, and this has been a period of exceptional volatility. How are you and your economic colleagues factoring all of this uncertainty?Seth: It's a great question and luminary minds like Neils Bohr, the Nobel Laureate in physics, and Yogi Berra, everyone's favorite prophet, have both said, ‘Forecasting is hard, especially about the future.' And this time, as you note, is even more so. So, what can we do? We try to come up with as many different scenarios as we can. We ask ourselves not just what's the most likely outcome, because there's uncertainty. The policy changes could come fast and furious. We also try to ask ourselves, if tariffs were to go back up from where they are now, how would that outcome turn out. If tariffs were to go away entirely, how would that turn out?You have to start thinking more and more, I think, in terms of scenarios.Serena:  And does this, in your view, change how much or how little investors should focus on the macro economy?Seth: Well, I think it means that investors have to focus every bit as much on the macro economy as they have in the past. I think it's undeniable that if we're right – and the U.S. economy slows down materially, and the global economy slows down with it – longer-term interest rates are probably going to come down along the lines of what our colleagues in interest rate strategy think. That makes a lot of sense to me. I think the trickier part though is knowing where the macro economy is going.We've got our forecast, but we are ready to make a revision if the facts change. And I think that's the trickier part for investors. The macro economy still matters but having a lot of conviction about where it's going, and as a result, what it means for asset prices? Well, that's the trickier part.Serena, you've been asking me lots of questions and they've been great questions, but I'm going to turn the table. I'm going to start asking questions right back to you.But we probably have to save that for another episode. So, let's pause it there.Serena: That sounds great Seth.Seth: And to the people listening, I want to say thanks for listening. And if you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or a colleague today.

Ali Velshi is joined by Rep. Don Bacon (R-NE), 2008 Nobel Laureate in Economics Paul Krugman, Professor of Law at NYU Melissa Murray, NBC News Senior National Security Analyst Frank Figliuzzi

What if the financial advice you trust is actually hurting your future? Mark Matson believes it is, and he has the data to prove it.   In this episode, I sit down with Mark Matson, founder of Matson Money and a pioneer in the evidence-based investing movement. With over $10 billion in assets under management, Mark has helped thousands of families and advisors break free from Wall Street myths, media-driven panic, and the illusion of market timing.   But Mark didn't start in finance. In fact, he nearly gave up on the entire industry — until a few key realizations (and one powerful idea from a Nobel Laureate) reshaped his approach to wealth entirely.   We talk about: The dangerous psychology behind most investing decisions and how to fix it Why traditional financial advice often fails to deliver real value What Wall Street doesn't want you to understand about your money The importance of storytelling in transforming investor behavior Why “doing nothing” is sometimes the smartest move in volatile markets   Mark also shares how he trains financial advisors to become coaches — not salespeople — and why aligning your portfolio with purpose is key to long-term success.   Whether you're an investor, advisor, or entrepreneur, this conversation will change how you think about money — and what it really means to grow wealth with integrity and intention.   Mark Matson is an American entrepreneur, author, and innovator in the fields of investing science and financial education. He is the creator of educational experiences, platforms, and tools that make Nobel Prize winning investing research accessible to investors and transform their relationship to money. Most notably, he is the creator of The American Dream Experience and the Matson Method.   Get Mark's book here: https://rb.gy/h4brr0 Experiencing The American Dream: How to Invest Your Time, Energy, and Money to Create an Extraordinary Life   Here are some free gifts for you: Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach   McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf   Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

This Is an original interview with one of the great Nobel Laureate who is talking about the development of life in the universe.

Three Nobel Peace Prize-winning organizations have jointly sent a letter to U.S. President Donald Trump and Russian President Vladimir Putin, urging them to meet face-to-face and reach an agreement on nuclear disarmament.

Nobel Laureate psychologist, Daniel Kahneman, was a pioneer of behavioural economics and among the most influential thinkers of recent decades. Professor Pete Lunn, head of the ESRI's Behavioural Research Unit, profiled Kahneman for The Brendan O'Connor Show.

In a world where nearly 1.4 billion adults still lack access to basic financial services, the promise of technology to bridge this gap has never been more critical. Our exclusive roundtable from the Surfin AI Fintech Forum 2025 in Manila brings together three visionary leaders -- a venture capitalist, a nuclear physicist turned fintech CEO, and Nobel Laureate in economics, who are supporting the growth of a company at the forefront of this transformation.Timestamps(00:05) How a nuclear physicist turned fintech CEO, Nobel laureate in economics, and Singaporean venture capitalist joined forces to bridge AI with financial inclusion;(09:39) Managing Risks of an Increasing Techno Nationalism to Build a Truly Global Fintech;(17:13) Bringing Together Financial Inclusion and Agentic AI;About who you are on call withYanan Wu is is CEO and founder of Surfin. Dr Wu has over 26 years of global investment experience, serving institutions and family offices, including stints at CITIC Prudential Fund and TD Asset Management Canada. He is no stranger to fintech as well, having launched and grown a robo-advisory startup prior to Surfin. He received a Ph.D in statistical physics from University Western Ontario in Canada and completed his post-doctoral research at Los Alamo National Lab in the USA.Michael (Mike) Spence is an American economist who, with George A. Akerlof and Joseph E. Stiglitz, won the Nobel Prize for Economics in 2001 for laying the foundations for the theory of markets with asymmetric information. Spence studied at Yale University (B.A., 1966), the University of Oxford (B.A., M.A., 1968), and Harvard University (Ph.D., 1972). He taught at Harvard and at Stanford University, serving as dean of the latter's business school from 1990 to 1999. In 2010 he became a professor at New York University's Leonard N. Stern School of Business. He is the author of the book, “The Next Convergence: The Future of Economic Growth in a Multispeed World,” Ferrar, Straus and Giroux, May 2011. Spence holds a BA in philosophy from Princeton University (1966), a BA/MA in mathematics from Oxford University (1968), and a PhD in Economics from Harvard University (1972).Yinglan Tan founded Insignia Ventures Partners and is the Founding Managing Partner. Insignia Ventures Partners is a Southeast Asian early-to-growth stage venture capital firm that debuted in 2017 and manages capital from premier institutional investors including sovereign wealth funds, foundations, university endowments and renowned family offices from Asia, Europe and North America. Portfolio companies include GoTo (IDX: GOTO), Appier (TSE: 4180), Carro, Ajaib, Shipper, Tonik, Flip, Fazz, Aspire, Super, Groww, J&T and many other technology market leaders. Prior to founding Insignia Ventures Partners, Yinglan was Sequoia Capital's first hire and Venture Partner in Southeast Asia. He also serves on the International Board of Stars – Leaders of the Next Generation, the Singapore Government's Pro Enterprise Panel. He is also a Board Member at Hwa Chong Institution and an Adjunct Associate Professor at the National University of Singapore. Yinglan was educated at Stanford and Carnegie Mellon and completed executive programs at Harvard, Wharton, Cambridge and Oxford.Follow us on LinkedIn for more updatesCheck out Insignia Business Review for more insightsSubscribe to our monthly newsletter for all the news and resourcesDirected by Paulo JoquiñoProduced by Paulo JoquiñoThe content of this podcast is for informational purposes only, should not be taken as legal, tax, or business advice or be used to evaluate any investment or security, and is not directed at any investors or potential investors in any ⁠⁠⁠⁠⁠⁠Insignia Ventures⁠⁠⁠⁠⁠⁠ fund. Any and all opinions shared in this episode are solely personal thoughts and reflections of the guest and the host.

Send us a textIt was an honor and privilege to interview Nobel Laureate Dr. Ignarro. From humble Italian roots to a breakthrough medical discovery. In this enlightening conversation, Dr. Lou Ingnarro shares his Italian heritage, family history, and the journey that led him to win the Nobel Prize in medicine. He discusses the significance of nitric oxide in health and medicine, its discovery, and its impact on various medical treatments, including Viagra. Lou emphasizes the importance of curiosity and education in pursuing a career in science, reflecting on his upbringing and the influence of his parents. The conversation also touches on the challenges of obtaining Italian citizenship and the personal connections to his roots.Lou Ingnato's family hails from Napoli and Sicilia.He was awarded the Nobel Prize in medicine in 1998.Nitric oxide is crucial for cardiovascular health.Curiosity played a significant role in Lou's scientific journey.Education can come from personal motivation, not just formal schooling.Lou's parents never attended school, yet they inspired his success.Nitric oxide has applications in treating erectile dysfunction and hypertension.Exercise and diet can boost nitric oxide levels in the body.Lou has visited Italy over 50 times since winning the Nobel Prize.He published a memoir titled 'Dr. No' about his life and discoveries."I am known as the father of Viagra.""You can boost nitric oxide with exercise.""You need to be curious in life.""Curiosity is key to scientific discovery.""My parents never went to school."Turnkey. The only thing you'll lift are your spirits.Dr. NOin this fascinating memoir, Dr. Ignarro opens up and shares intimate details about his life journey.Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showPurchase my book "Farmers and Nobles" here or at Amazon.

Laser-cooling expert looks to the future of quantum technologies

This episode features Professor Roger Myerson, Nobel Laureate (2007) and Professor at the University of Chicago. We discuss the war in Ukraine through his on-the-ground experience and academic expertise. Professor Myerson reflects on the political, social, and technological shifts he has witnessed since the war began. The conversation examines how Ukraine is adapting to the change in U.S. foreign policy under President Trump, the prospects for peace, the role of NATO and other security guarantees, and the gap between Europe's economic power and military response.  This podcast is produced in partnership with the Pearson Institute for the Study and Resolution of Global Conflicts. For more information, please visit their website at www.thepearsoninstitute.org.  Podcast Production Credits: Interviewing: Isabella Nascimento, Viktoriia Shcherba Editing: Megha Viswanath Production: Isabella Nascimento 

In this groundbreaking conversation, we dive deep into the science and power of nitric oxide—a tiny molecule with a massive role in fertility, circulation, immune health, and cellular communication. From supporting erections and ovulation to influencing embryo development and even brain function, nitric oxide is proving to be one of the most overlooked yet critical elements in reproductive and overall health.Joined me in this conversation with Dr Nathan Bryan!Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University School of Medicine in Shreveport, where he was the recipient of the Dean's Award for Excellence in Research. He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute. After a two-year post-doctoral fellowship, in 2006, Dr. Bryan was recruited to join the faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology. Dr. Bryan has been involved in nitric oxide research for the past 20 years and has made many seminal discoveries in the field. His many seminal discoveries have resulted in dozens of issued US and International patents, and the product technology resulting from his discoveries and inventions has improved patient care worldwide. Dr. Bryan is a successful entrepreneur and the Founder of HumanN, Inc, Pneuma Nitric Oxide, LLC, Nitric Oxide Innovations, LLC, and Bryan Nitriceuticals, LLC. His product technology is responsible for hundreds of millions of product sales worldwide. Most recently, Dr. Bryan serves as Founder and CEO of Nitric Oxide Innovations, LLC, a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of nitric oxide-based therapies. NOI has several drug candidates in phase 3 clinical trials. Dr. Bryan is an international leader in molecular medicine and nitric oxide biochemistry.

Chad and Mike invite Nobel Laureate Dr. Randy Schekman to discuss his research into yeast cells and the mechanisms that yeast (and human) cells use to direct traffic. Proteins that are created within the cell need to be pushed into the appropriate places and Schekman is one of the discoverers of those mechanisms.Enjoy these episodes ad free!

On March 16, the New York Times published “We Were Badly Mislead About The Event That Changed Our Lives”. It reports that 77 Nobel Laureates and 31 scientific societies were involved in the cover up that included deliberately planning to mislead journalists. (Actually, the NYT can be accused of failing to do its job). Guy Hatchard analyses what really took place in New Zealand and elsewhere under the heading of "A strange mental illness is spreading via infected information networks". It's a most revealing discussion. Also we comment on “The climate scam is over”; a ground breaking study using AI to debunk the man-made climate crisis narrative. Who would've thought. (Michael Mann is getting destroyed every which way)! And the Mailroom with Mrs Producer is excellent. File your comments and complaints at Leighton@newstalkzb.co.nz Haven't listened to a podcast before? Check out our simple how-to guide. Listen here on iHeartRadio Leighton Smith's podcast also available on iTunes:To subscribe via iTunes click here See omnystudio.com/listener for privacy information.

Reparations for the crimes of the transatlantic slave trade “can't be quantified” given the vast historical sweep of human history, according to the first Black African to be awarded the Nobel Prize for Literature, Wole Soyinka.The longtime Nigerian democracy activist was at UN Headquarters in New York to take part in commemorations for the International Day of Remembrance of the Victims of Slavery, telling the General Assembly that it remains crucial to confront centuries of wrongdoing.Ana Carmo sat down with him in our UN News studio following the event and asked him to outline his main message to the international community.

Shipbreaking Updated: The Most Dangerous Job in the World In mid 2024, students in Bangladesh organized mass protests and brought down the repressive government of Sheikh Hasana. The country is now under a caretaker government of Muhammed Yunus, a Nobel Laureate who is attempting reforms. Months before this Monsoon Revolution, we told you about shipbreaking, the waste management of industrial ships sent to Bangladesh that has been dubbed “the most dangerous job in the world.” Guest Rizwana Hasan was then the country's only environmental lawyer and fierce advocate against the shipbreaking industry. Today, she is the new government's Adviser for Environment, Forest and Climate Change. What has changed for shipbreakers under this new government. This week, host Ngofeen Mputubwele revisits last year's episode and catches up with Human Rights Watch researcher Julia Bleckner to understand this new moment in Bangladesh, and how it will impact shipbreaking. Julia Bleckner: Senior Researcher for the Asia Division and Global Health Initiative at Human Rights Watch Rizwana Hasan: Adviser for Environment, Forest and Climate Change of Bangladesh

Winner of the Nobel Prize for Literature, Abdulrazak Gurnah reveals what drives him as an author, discusses universality, examines what "home" means, reflects on his decision to leave his native Zanzibar as an 18 year-old, and talks about his eleventh novel, Theft. 

MAKE HISTORY WITH US THIS SUMMER:https://demystifysci.com/demysticon-2025PATREON https://www.patreon.com/c/demystifysciPARADIGM DRIFThttps://demystifysci.com/paradigm-drift-showPATREON: get episodes early + join our weekly Patron Chat https://bit.ly/3lcAasBMERCH: Rock some DemystifySci gear : https://demystifysci.myspreadshop.com/allAMAZON: Do your shopping through this link: https://amzn.to/3YyoT98SUBSTACK: https://substack.com/@UCqV4_7i9h1_V7hY48eZZSLw@demystifysciAndré Koch Torres Assis is a professor of Physics at Brazil's University of Campinas, an invited speaker at our Beyond the Big Bang meeting this June, and a brilliant historian who has devoted his life to uncovering the missing pieces of scientific progress that lie scattered in the untranslated works and letters of the great physicists of the last century, including Wilhelm Weber and André-Marie Ampère. Today, we primarily occupy ourselves with alternative explanations to the Cosmic Microwave Background radiation. Many listeners will be familiar with Pierre Marie Robitaille's theory that the CMB is produced due to the hydrogen bond lattice of the oceans. Here, Assis lays out a different theory - championed by at least four Nobel Laureates - that the CMB isn't the afterglow of the Big Bang - it's simply the temperature at which the cold, dark objects of space are equilibrated against the background light of the stars. (00:00) Go!(00:05:09) Upcoming conference(00:07:18) Translation and Historical Insights(00:12:47) Controversies in Electrodynamics(00:24:27) Current and Magnetism Debates(00:27:25) Philosophical Doubts in Scientific Validation(00:31:13) Electromagnetism and Historical Contributions(00:36:11) Evolution of Electrodynamic Theories(00:42:14) Cosmic Background Radiation and Paradigm Shifts(00:49:54) Historical Predictions of Cosmic Temperature(00:56:38) Theoretical Insights on Cosmic Temperature(01:04:24) Cosmic Rays and Temperature Measurements(01:10:05) Notable Contributions and Theories Supporting Infinite Universe(01:15:03) Mechanisms Behind Redshift Interpretations(01:25:36) Understanding Fluorescence and Redshift(01:28:22) Historical Perspectives on Cosmology(01:30:20) Hubble's Law and Its Misinterpretations(01:33:41) Challenges of Cosmic Expansion Concepts(01:39:47) Controversies in Redshift and Galaxy Formation(01:44:00) Quasars and Intrinsic Redshift Theories(01:57:16) Redshift and Universe Expansion Debate(02:00:27) Hubble's Legacy and Cosmological Views(02:04:55) The Search for Alternative Redshift Theories #Cosmology, #Astrophysics, #QuantumPhysics, #Quasars, #ScientificRevolution, #NewPhysics, #Electrodynamics, #SpaceScience, #CosmicMicrowaveBackground, #InfiniteUniverse, #PhilosophyOfScience, #philosophypodcast, #sciencepodcast, #longformpodcastCheck our short-films channel, @DemystifySci: https://www.youtube.com/c/DemystifyingScience AND our material science investigations of atomics, @MaterialAtomics https://www.youtube.com/@MaterialAtomicsJoin our mailing list https://bit.ly/3v3kz2S PODCAST INFO: Anastasia completed her PhD studying bioelectricity at Columbia University. When not talking to brilliant people or making movies, she spends her time painting, reading, and guiding backcountry excursions. Shilo also did his PhD at Columbia studying the elastic properties of molecular water. When he's not in the film studio, he's exploring sound in music. They are both freelance professors at various universities. - Blog: http://DemystifySci.com/blog - RSS: https://anchor.fm/s/2be66934/podcast/rss- Donate: https://bit.ly/3wkPqaD- Swag: https://bit.ly/2PXdC2y SOCIAL: - Discord: https://discord.gg/MJzKT8CQub- Facebook: https://www.facebook.com/groups/DemystifySci- Instagram: https://www.instagram.com/DemystifySci/- Twitter: https://twitter.com/DemystifySciMUSIC: -Shilo Delay: https://g.co/kgs/oty671

Foresight Africa podcast host Landry Signé speaks with James Robinson, 2024 Nobel Laureate in economics and University Professor at the University of Chicago's Harris School of Public Policy, about the critical importance of societal institutions in driving economic prosperity in Africa and the imperative of homegrown solutions in unlocking the continent's potential. Show notes and transcript Foresight Africa podcast is part of the Brookings Podcast Network. Subscribe and listen on Apple, Spotify, Afripods, and wherever you listen to podcasts. Send feedback email to podcasts@brookings.edu.

Nobel laureate Dr. Morten Meldal, Professor of Chemistry at the University of Copenhagen, revolutionized the field of chemistry with his pioneering work on click chemistry—earning him the 2022 Nobel Prize in Chemistry. On this exciting episode of Let's Talk Chemistry edited by Presley Vu, hosts Jason Lu and Neel Youts dive into our interview with Dr. Meldal, exploring his journey from molecular modeling to groundbreaking discoveries in peptide synthesis and bioorthogonal chemistry. Dr. Meldal shares insights into the applications of click chemistry in drug development, material science, and even green chemistry solutions. From his experiences at the Carlsberg Laboratory to the moment he received the Nobel Prize, Dr. Meldal reflects on his career, collaborations, and the future of chemistry. We hope you enjoy!

Nobel Laureate and MIT economist Simon Johnson said he's worried about the growth- and institution-damaging actions of the Trump administration, but relieved he seems willing to leave monetary policy to the Federal Reserve. 

February 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma technology, which paved the way for monoclonal antibodies. Ralph Minter, Biotech CSO/CTO, discusses this important milestone with a true pioneer in the field, Sir Greg Winter, Nobel Laureate and one of the key figures in the development of therapeutic antibodies. 

Transcript with time code:  https://cuttingedgehealth.com/wp-content/uploads/2025/02/Transcript-47-Dr-Venki-Ramakrishnan.pdf   In this episode, Jane interviews Nobel Prize winner Venki Ramakrishnan, a molecular biologist who offers a balanced perspective on the anti-aging field.   Ramakrishnan discusses various promising areas of anti-aging research, including caloric restriction drugs like rapamycin, senolytics to target senescent cells, and stem cell therapies. He emphasizes the importance of clinical trials and cautions against rushing into unproven treatments. The conversation covers lifestyle factors that can promote healthy aging, such as regular exercise, proper nutrition, and maintaining social connections.   Ramakrishnan shares personal insights, including his father's experience of maintaining an active lifestyle until age 99. He also touches on his own career journey and winning the Nobel Prize. Throughout the interview, he stresses the need for a scientific approach to anti-aging research while acknowledging the urgency felt by many to combat aging. The podcast provides a thoughtful exploration of the current state of anti-aging science, balancing excitement for potential breakthroughs with the need for rigorous scientific validation.   *****   Venki Ramakrishnan shared the 2009 Nobel Prize in Chemistry for uncovering the structure of the ribosome. A National Academy of Sciences member, Venki runs his research group at the MRC Laboratory of Molecular Biology in Cambridge, England. From 2015 to 2020, he served as president of the Royal Society, one of the world's oldest scientific organizations. He is the author of the frank scientific memoir Gene Machine: The Race to Decipher the Secrets of the Ribosome and Amazon bestselling book Why We Die: The New Science of Aging and the Quest for Immortality.   *****   Cutting Edge Health podcast website: https://cuttingedgehealth.com/   Cutting Edge Health Social and YouTube:   YouTube channel: youtube.com/@cuttingedgehealthpodcast   Instagram - https://instagram.com/cuttingedgehealthpodcast   Facebook - https://www.facebook.com/Cutting-Edge-Health-Podcast-with-Jane-Rogers-101036902255756   Please note that the information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Cutting Edge Health podcast, its employees, guests and affiliates assume no liability for the application of the information discussed.   Special thanks to Alan and Maria on the Cutting Edge Health team!    

Part 2 of 2: Our guest today is Oguzhan Atay, Co-founder & CEO of BillionToOne. BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They work to improve disease detection by counting molecules with their proprietary molecular counting platform. They place patients at the forefront of everything they do and are currently applying their proprietary technology to non-invasive prenatal screening and liquid biopsy. Oguzhan holds a Ph.D. from Stanford in Systems Biology, where he implemented machine learning algorithms and mathematical models to solve specific problems in cellular biology and developed a data-driven mathematical framework to simplify the analysis of complex biological networks. He also has a degree in Molecular Biology from Princeton, as well as minors in Computer Science, Physics, and Applied Mathematics. Oguzhan not only combines deep technical expertise with visionary leadership, but he also has an incredibly inspirational immigrant journey, which makes this series a must-listen for first-time founders, scientists, and industry leaders alike.

Nobel Laureate and journalist Maria Ressa has spent her career standing up for freedom of speech in support of democracy and peace

Jeff and Rebecca discuss the new novel by the 2024 Nobel Laureate in Literature, Han Kang. To listen to the full episode, become a member of the Book Riot Podcast Patreon, if you aren't already. Learn more about your ad choices. Visit megaphone.fm/adchoices

Having read more than 1,000 books about investing, Ryan Zabrowski decided to author his own, a 500-page tome titled Time Ahead: Investor's Guide to Prosperity and Impact, inspired by the lessons of Warren Buffett, Benjamin Graham, and Nobel Laureates from Columbia, Penn, Yale and the University of Chicago. (01/2025)

Having read more than 1,000 books about investing, Ryan Zabrowski decided to author his own, a 500-page tome titled Time Ahead: Investor's Guide to Prosperity and Impact, inspired by the lessons of Warren Buffett, Benjamin Graham, and Nobel Laureates from Columbia, Penn, Yale and the University of Chicago. (01/2025)

A CPI print driven rally Rebalancing Investment Portfolios and Risk Autonomous Driving's Impact on Society Guest - Ryan Zabrowski, CFP,MSF - Author of Time Ahead  NEW! DOWNLOAD THIS EPISODE'S AI GENERATED SHOW NOTES (Guest Segment) Ryan Zabrowski, CFP, MSF Having read more than 1,000 books on investing – and authored his own 500-page book in 2024 – Ryan's disciplined investment strategy has long been inspired by the lessons of Warren Buffett, his teacher Benjamin Graham, and Nobel Laureates from Chicago, Columbia, Pennsylvania, and Yale Universities. As a result, Ryan favors owning sustainable, high-quality businesses and arbitrage strategies designed to profit, regardless of economic or interest rate direction. Ryan's career in finance began in 1994. Early on, he focused on financial analysis and financial statement analysis. Over the past 23 years, Ryan has worked in financial and investment management at Washington University Endowment, Morgan Stanley, and Merrill Lynch, before joining Krilogy in 2019. Given his extensive investment knowledge and experience, Ryan has become an integral member of the firm's Investment Committee, which manages Krilogy's model investment portfolios. In this role, Ryan helps conduct investment research, voting on investment strategies and portfolio positions, monitoring fund performance, and analyzing market conditions. GET RYAN'S BOOK - TIME AHEAD Most important to Ryan, however, is sharing his insights and perspectives with his team's clients. Experience tells him that clients who understand what they own and why are best able to minimize emotion and make fact-driven decisions that drive positive, long-term results. Ryan's rigorous and ongoing industry training allows him to provide clients with an extra measure of knowledge, in addition to requiring a fiduciary level of care. Follow @RyanZabrowski Learn More at http://www.ibkr.com/funds Follow @andrewhorowitz Looking for style diversification? More information on the TDI Managed Growth Strategy - https://thedisciplinedinvestor.com/blog/tdi-strategy/ eNVESTOLOGY Info - https://envestology.com/ Stocks mentioned in this episode: (JPM), (GS), (WFC), (MS), (BAC). (NVDA), (AAPL)

For bonus content, please join us on Patreon at - https://www.patreon.com/posts/live-now-special-11972532 This special show on what REALLY caused the LA wildfires features David Sirota, Yasha Levine, Natali Segovia, Steven Donziger, Meagan Day & Josh Olson. David Sirota is an award-winning journalist and bestselling author living in Denver, Colorado. He was nominated for an Academy Award for helping Adam McKay create the story for the film DON'T LOOK UP. Sirota is the founder and editor of The Lever, the creator of Audible's MELTDOWN podcast and . the MASTER PLAN podcast. Natali Segovia (Quechua) is an international human rights attorney who currently serves as Executive Director of the Water Protector Legal Collective. Natali's work focuses on the protection of the Earth and the rights of Indigenous Peoples affected by forced displacement, and human rights violations as extractive industry and mass development projects. Over the past 15 years, her international work has focused on addressing human rights violations as a result of extractive industry and mass development projects in rural, "unseen" areas in countries including Colombia, Peru, Bolivia, and Brazil. She currently serves on the Scientific Committee of the Monique and Roland Weyl People's Academy of International Law and on the Board of Directors for Indigenous Peoples Rights International. Yasha Levine is a Russian-American investigative journalist, writer, and filmmaker. He's the author of "Surveillance Valley: The Secret Military History of the Internet," "A Journey Through California's Oligarch Valley," "The Koch Brothers: A Short History" and "The Corruption of Malcolm Gladwell." He's the co-host of The Russians podcast and writes at https://yasha.substack.com/ Steven Donziger is a human rights and environmental lawyer who was imprisoned for successfully suing Chevron for poisoning the water in the Ecuadorian Amazon. The prosecution of Steven Donziger, which has been condemned by the United Nations, Greenpeace, Amnesty International, Amazon Watch, and 64 Nobel Laureates, was a literal corporate prosecution. After the Southern District of New York refused to prosecute Donziger, the judge assigned a corporate firm which had represented Chevron to go after him. The judge also made the unusual move of handpicking the judge to oversee the case and chose a judge who is part of the Right Wing Federalist Society which gets funding from.... you guessed it... Chevron! Meagan Day is a writer and editor focusing on class, labor issues, economic inequality, and US politics. She is an editor at Jacobin, where she was previously a staff writer. The author of Maximum Sunlight (2016) and co-author of Bigger than Bernie (2020), her articles have appeared in numerous publications, including The New York Times, The Guardian, and The New Republic In 2022 she addressed the Oxford Union on the topic of the "American Dream" in a global context. Josh Olson is an Oscar nominated screenwriter, writer of the "Bronzeville" podcast, and host of "The Movies That Made Me." Dave and Josh co-hosted the podcasts "West Wing Thing" and "The Audit." ***Please support The Katie Halper Show *** For bonus content, exclusive interviews, to support independent media & to help make this program possible, please join us on Patreon - https://www.patreon.com/thekatiehalpershow Get your Katie Halper Show Merch here! https://katiehalper.myspreadshop.com/all Follow Katie on Twitter: @kthalps

Orhan Pamuk has traveled far and wide, around the world, across the page, and in the landscapes of his mind. Now he joins Erica Wagner to illuminate his craft. From his travels around the world to his reflections on fellow writers, from journal entries scrawled across the span of over a decade to the beginnings of his creative process, Orhan joins us to explore not only his artistic method, but also how daily happenings and larger currents have shaped his oeuvre. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Piezo touch and pressure-sensing ion channels are showing up everywhere as the explanation for physiologic phenomena, both at the macro and micro levels. Ardem Patapoutian, my friend and colleague at Scripps Research, discovered these receptors back in 2010 and was awarded the Nobel Prize in 2021 for his work. As you'll see/hear from our conversation, the field has exploded. And you'll get to know Ardem, who is such a fun, charismatic, and down-to-earth person. He also recently got a unique tattoo (videos below) and I wonder (unlikely) if any other Nobel laureates have one related to their discovery?!Below is a video clip from our conversation. Full videos of all Ground Truths podcasts can be seen on YouTube here. The current one is here. If you like the YouTube format, please subscribe! The audios are also available on Apple and Spotify.Transcript with links to audioEric Topol (00:07):Well, hello. It's Eric Topol with Ground Truths, and I've really got a special guest today. The first time for the podcast, I've been able to interview a colleague and faculty at Scripps Research, Ardem Patapoutian, who just by the way happens to be the 2021 Nobel Laureate in Physiology or Medicine. So welcome, Ardem. It's so wonderful to have you.Ardem Patapoutian (00:30):Thanks so much, Eric. Looking forward to chatting with you.Eric Topol (00:34):Well, this has been interesting because although I've known you for several years, I didn't research you. I mean, I had to learn about more than I even do. And of course, one of the great sources of that is on the Nobel Prize website where you tell your whole story. It is quite a story and not to review all of it, but I wanted to go back just before you made the call to move to Los Angeles from Beirut, Lebanon and with the scare that you went through at that time, it seemed like that was just extraordinary that you had to live through that.Ardem Patapoutian (01:11):Yeah, so I am of Armenian origin, but I was born in Lebanon and born in 1967, so I was eight years old when the civil war started. So it's a kind of bizarre childhood in the sense that with all the bombs and fighting in Lebanon. So it was tough childhood to have, but it was never personal. It was bombs and such. And so, the event you're talking about is, I happened to be kidnapped while crossing East to West Beirut. They only held me for four or five hours at first asking me questions to see who I am, but I think they pretty soon figured out that I was not a dangerous guy and they ended up letting me go. But before that, that incident really had a huge impact on me so that by the time I got home, I literally said, I'm out of here. I'm going to find a way to leave the country. And so, that's what, very quickly within a few months I packed and came to United States.Eric Topol (02:19):And how did you pick LA to be your destination?Ardem Patapoutian (02:22):Being from the Armenian community, there's a lot of Armenians in Los Angeles. My cousins already had moved there. They also grew up in Lebanon. And my brother, who's a few years older than me, got admitted to USC graduate school in engineering. So he was going to be there. So it made a lot of sense.Eric Topol (02:44):Oh yeah.Ardem Patapoutian (02:45):Unlike him, I came with no school or job prospects because it happened so fast that I kind of just left. One year I was at American University of Beirut for one year, but then just left and came here. So worked for a year in various jobs and then started going back to school to UCLA.Eric Topol (03:07):Yeah, I saw how there was about a year where you were delivering pizzas and before you got into UCLA, and that must have been an interesting off year, if you will. Well, the story of course, just to fast forward, you did your baccalaureate at UCLA, your PhD at Caltech, postdoc at UCSF, and then you came to Scripps Research 24 years ago along with Pete Schultz, and it's been quite an amazing run that you've had. Now, before we get into PIEZO receptors, the background, maybe you could help me understand, the precursor work seems to be all related to the transient receptor potential (TRP) series, also ion channels. They were of course related to whether it was heat and temperature or somatosensory. How do these channels compare to the ones that you discovered years later?Background on these Ion ChannelsArdem Patapoutian (04:09):Yeah, so the somatosensory neurons that innervate your fingertips and everywhere else in your body, their main job is to sense temperature and pressure. And this is very different than any other neuron or any other cell. So when you touch a hot stove that's burning hot, you need to know about that immediately within milliseconds or something cold. So the opposite side of it is pressure sensing, and it also comes in light touch, which is pleasant or a hammer hitting your finger, which is unpleasant. But all of these have the same characteristic anyway, that is your body has learned at the molecular level to translate a physical stimulus such as temperature and pressure into an electrical signal that neurons use to communicate with each other. But this idea of how you translate physical stimuli into chemical or electrical signal has been a long open question because as you know, most of our cells communicate by chemicals, whether that's hormones or small molecules, we know how that works, receptor bind to ligand, confirmational change and you get a kinase activation and that's enough. But here, how do you sense pressure? How do you sense temperature? It was just, there wasn't much known about that. And that's why our earlier work on TRP channels, which were temperature sensors came before the pressure. And so, they're very related in that sense.Eric Topol (05:52):The structure of these, if you were to look at them, do they look pretty similar? What the TRP as you say, and what you did back in the 2010 Science paper, which we'll link to, of course the classic paper where you describe PIEZO1 and PIEZO2, but if you were to look at this structures, would they look pretty similar?Ardem Patapoutian (06:14):No, that's a good question. And they absolutely don't. That's why finding these receptors were so hard. So if you go back to other sensory receptors, vision rhodopsin G-protein coupled receptor (GPCRs), larger G-protein coupled receptor look the same. So for example, when it was identified by chemically, that smell also works through G-protein coupled receptor. Richard Axel and Linda Buck, who also won the Nobel Prize, found those receptors by homology to visual GPCRs. The ion channels other than the fact that they crossed the membrane a few times or more, they have nothing else in common. If you looked at their structure, you can't even immediately tell they're ion channels. So you couldn't find these by structural homology or sequence homology. So you had to do something else. And usually that means functional screens and et cetera.Eric Topol (07:09):Well, yeah, and I'm in touch with the screening. We'll get to that and how you dig these up and find them. But the somatosensory ones are really interesting because I don't think a lot of people realize that when you have wasabi or you have Listerine mouthwash and feel the burn and that these are all mediated through these channels, right?Ardem Patapoutian (07:35):Yeah. So there's this whole field of chemesthesis, which means senses in your mouth, for example, that are not explained by taste transduction and olfactory. And these are actually by the same somatosensory neurons that help you sense temperature and pressure. And some of these receptors are the same. Their evolution has taken over and used them for many different things. The prime example of this is the capsaicin receptor that David Julius my co-laureate identified, which is also heat receptors. So all languages describe chili peppers as hot, and that's not a coincidence. It actually activates heat activated channel, and that's why we think of it as hot. And so, the same goes to another one of these TRP channels that you mentioned, which is TRPA1, and this one is also activated, but a lot of spicy foods other than the chili pepper active ingredient includes what's in garlic and onions and everything that has this burning sensation and chemicals of this and wasabi and chemicals of this are used in over the counter products like Listerine that cause that burning sensation.Eric Topol (08:54):So when you're chopping onions and it makes you cry, is that all part of it as well?Ardem Patapoutian (08:59):That's all TRPA1, yeah.The Discovery, A Test of PerseveranceEric Topol (09:01):It's wild. Now, this was the groundwork. There were these heat temperature and somatic sensory, and then you were starting to wonder what about touch, what about out pressure and proprioception. And so, you went on a hunt, and it's actually kind of an incredible story about how you were able to find out of these cells that you had, screening hundreds or I guess you got to 72 different small interfering RNA blocking that you finally found the one. Is that right?Ardem Patapoutian (09:37):That's right. So in retrospect, looking back at it, I think there's such an interesting scientific message there. And so, many of us were looking for this touch pressure sensors and we were all looking in the DRG sensory neurons that are complicated heterogeneous, they don't divide. It's not easy to do a screen on them. And ultimately after a lot of failures, what worked for us is to take a step back and ask a much more simpler question. And that was, can we find one of these cell lines that you could easily homogeneously grow in a culture dish, if they respond to mechanical force, can we find our channel there? And then go back and look if it's relevant in vivo for what process. So I think the message is ask the simplest question to answer the question you're after. And finding what that is, is actually the challenge lots of times.Ardem Patapoutian (10:36):But yeah, that's what Bertrand Coste in my lab did is found a simple cell line that neuroscientists had been using for a hundred years and somehow found that they over overexpressed this channel because you can record from them, you can push them and record the currents from them. And then it became a simpler question of finding it. It still took a whole year. He made a list and one by one knocking them out and looking at it. And finally, as you say, number 72 was the hit. When he knocked that out, the current was gone. And that's where we started believing that we have what we were looking for.Eric Topol (11:12):Were you all ever about ready to give up at that point?Ardem Patapoutian (11:16):Oh yeah. I mean that's another lesson. These are postdocs doing the work, right? And they're here three, four years and this was coming close to end of two years, and he didn't have anything yet. So we started talking about having a backup project and he started that and we said, okay, we were ordering this oligos 30 at a time because they're expensive. And so, the first 30 nothing, the second 30 nothing. And how many more are we going to do before we potentially give up? And we said, well, let's do at least a third and then decide, thank goodness it was in that last set.Eric Topol (11:54):Wow, that is so wild. Now what's happened since this discovery, which I guess when you published it in 2010, so it means 14 years ago, but we're on this exponential growth of learning that these piezo receptors are everywhere. They're doing everything. In fact, I recently put on Bluesky, PIEZO ion channels are to human physiology as GLP-1 drugs are to treating many diseases because it's just blowing up. And you've published on some of these of course, on itch and bladder function and vascular function. We'll get to maybe malaria, I mean, but even the cover of Science recently was about wet dog shakes and how animals shake because of water. These receptors are so fundamental to our function. So maybe you could comment, 15 years ago when you were doing the work and you're making this discovery, did you ever envision it was going to blow up like this?Ardem Patapoutian (12:57):Not to this level, but I should have. I think that this idea, again, that most of cell communication is through chemicals is of course a lot of it is true.Ardem Patapoutian (13:12):But it would be ridiculous for evolution to ignore all the physical forces, the pressures that cells experience. And once they do, you would think you would put an instructive way of sensing this pressure signal and using it beneficially to the system or the cell. And so, when we used to talk about pressure sensing at the beginning, there were a couple of touch, pain, maybe proprioception, hearing are like the poster children of pressure sensing. But I think what these molecules, as you say is enabling us is finding out the much more wider role that pressure sensing is playing in physiology and in disease that no one had thought seriously about. And this is, I compare sometimes the finding the PIEZO molecules. You're going in a dark room, and you need to find a door to get into there. And PIEZO is kind of that finding the door once you get in, now you use that molecule now to find physiology instead of the opposite way around. So by pursuing PIEZO expression and function, we're finding all these new roles that they play in physiology and in disease that we didn't think about. And because they're so specialized to sense tension, membrane tension, they don't do anything else. So if you see them expressed somewhere or if you see a function for them, you can bet that they are playing a role in sensing pressure. A lot of biology has kind of come from this hypothesis.Eric Topol (15:00):Well, I mean it is so striking to see the pervasiveness, and I do want to go back just for a second because when you name them PIEZO, you named it after the Greek word. How did you come to that name?Ardem Patapoutian (15:13):So Bertrand and I were actually sitting on Google Translate and we were typing pressure and trying to see what it's like in Greek or in Latin or different languages. His native French and my Armenian and píesi in Greek is pressure. And of course, what's really cool is that the word that more people know about this is piezoelectric device.Eric Topol (15:41):Oh, right.Ardem Patapoutian (15:41):Actually, translates physical force into electricity and vice versa. And in a way, this is a little molecular machine that does the same thing, and he uses this piezoelectric device to actually push on the cell. That's his assay. So it all came together as a very appropriate name for this gene and protein.Call from the Nobel CommitteeEric Topol (16:04):Oh really, it's perfect. And you get to name it, even that's fun too, right? Now we're going to go to getting the call at 2:00 AM, but it didn't come to you because your phone from the Nobel Committee was on ‘do not disturb' and your 94-year-old father, Sarkis. How did the Nobel Committee know to get ahold of him? How did they reach him in the middle of the night?Ardem Patapoutian (16:37):Yeah, so I mean, since receiving it, I've had conversations with various committee members, and they are very resourceful folks, and they have assistants who throughout the year collect information on all potential people who might win. They're also doing last minute searches. So they looked for other Patapoutian's in California. So they just called my dad who initially yelled at them for disturbing him at 2:00 AM.Eric Topol (17:17):And he could get through to you because he was not on your list of ‘do not disturb' or something like that.Ardem Patapoutian (17:22):I didn't even know this. And I don't know if the policy has changed, but in some phones the ‘do not disturb' if it's called by someone who's in your contacts or favorites.Ardem Patapoutian (17:34):After I think they called twice and they get through, and that's how.Getting a Tattoo!Eric Topol (17:39):That's amazing. Wow. Well, that's quite a way to find out that you're getting recognized like this. Now recently you got a tattoo, which I thought was really remarkable, but we're going to put that of course in the post. Tell us about your decision to get the PIEZO channel on your arm.Ardem Patapoutian (18:02):So as you can tell, I'm obsessed about PIEZO and it's been good to me. And I had the idea a while ago, and my very wise wife, Nancy Hong, said that you might be going through midlife crisis. Why don't you wait a year? If you still believe in it, you should do it. And that's what I did. I waited a year, and I was like, I still want to do it. And I guess I could show it. Here it is.Eric Topol (18:32):Oh yeah, there it is. Oh wow.Ardem Patapoutian (18:33):What's cool is that I can pretty much flex to show the activation mechanism because the channel is like bent like this in the plasma membrane. When it's stretched, it opens and it actually flattens like this. So I feel like other than being a tattoo, this is both performance art and instructional device. When I'm giving talks without PowerPoint slides, I could give a demonstration how this ion channel works.[Below is from a presentation that Ardem recently gave, the Harvey Lecture, at Rockefeller University.]Eric Topol (19:04):It's wild. Now how did you find a tattoo artist that could, I mean, it's pretty intricate. I mean, that's not your typical tattoo.Ardem Patapoutian (19:14):Yeah, I put it up on social media that I was thinking of doing this, and many scientists are into tattoos, so I actually got so many recommendations. And one of them was a local here in San Diego, and she is very popular. I waited six months to get this, I was on a waiting list. The appointment was six months off when we made it. So she's very popular and she's very good.Eric Topol (19:45):Was it painful to get that done?Ardem Patapoutian (19:47):Well, that's actually really cool, right? Because PIEZO2 is involved in pain sensation, and I felt it while it was being tattooed on my arm. The whole day, I was there like six and a half hours.New Prospect for Pain MedicationEric Topol (20:00):Oh my gosh. Wow. Now that gets me to pain because, I'd like you to talk a bit about the people that don't have mutations or loss of function PIEZO receptors and also what your thoughts are in the future as to maybe we could develop a lot better pain medications.Ardem Patapoutian (20:22):Yeah, we're working on it. So you're right. One of the great parts of the science story, and this is mainly the work of Alex Chesler and Carsten Bönnemann at the NIH, where they identified people who came to the clinic for undiagnosed conditions, and they were uncoordinated and had difficulty walking. And when they did whole-exome sequencing, they found that they had mutations in PIEZO2, there were loss of function, as you say. So complete loss on both chromosomes. And when they started testing them, they realized that just like we had described them in animal models, humans without PIEZO2 as well, didn't sense touch, don't have proprioception. This sense of where your limbs are, that's so important for balance and most other daily functions that we take it for granted. So they were completely lacking all of those sensations. They also do not feel their bladder filling.Ardem Patapoutian (21:26):And so, they have learned to go on a schedule to make sure they don't have accidents. And many of these projects that we've done in the lab collaboration with Alex Chesler, et cetera, have come from the observations of what else these individuals experience. And so, it's been a great kind of collaboration communication between mechanistic animal model studies and the clinic. And so, one of the things that these individuals don't sense in addition to touch, is something called tactile allodynia, which is simply when touch becomes painful. You and I experienced this after small injury or sunburn where just touching your shoulder becomes painful, but for peripheral neuropathy and other neuropathic pain conditions, this is one of the major complaints that individuals have. And we know from the NIH studies that these individuals don't have this tactile allodynia. So touch becomes painful and doesn't apply to them, which tells us that if we block PIEZO2, we can actually get interesting relief from various aspects relative to neuropathic pain on other pain related neuropathies. But given everything we talked about, Eric, about how this is important for touch and proprioception, you don't want to make a pill that blocks PIEZO2 and you take it because this will have some serious on target side effects. But we are developing new compounds that block PIEZO2 and hope that it might be useful, at least as a topical medication pain and other indications. And we're actively working on this, as I said.Eric Topol (23:15):Yeah, I mean the topical one sounds like a winner because of peripheral neuropathy, but also I wonder if you could somehow target it to sick cells rather than if giving it in a systemic targeted way. I mean it has tremendous potential because we are on a serious hunt for much better relief of pain than exists today.Ardem Patapoutian (23:41):Absolutely.Eric Topol (23:42):Yeah. So that's exciting. I mean, that's another potential outgrowth of all this. Just going back, I mean the one that prompted me in November to write that about the human physiology in PIEZO, it was about intestinal stem cell fate decision and maintenance. I mean, it's just everywhere. But the work you've done certainly now has spurred on so many other groups to go after these different and many unanticipated functions. Were there any ones, of course, you've been pretty systematically addressing these that actually surprised you? You said, oh, are you kidding me when you read this? I never would've guessed this, or pretty much they followed suit as things were moving along.Ardem Patapoutian (24:33):So one of them is this role in macrophages that I found fascinating that we found a few years ago. So again, this came from human studies where PIEZO1 gain-of-function mutations. So in relation to loss of function, their gain-of-function where there's more activity given a certain amount of pressure. They have dehydrated red blood cells, which I'm not going to talk about right now. But they also have shown that in these patients, individuals, it's not really that pathological. They also have age-onset iron overload. What does that have to do with pressure sensing? And we brought that information into animal models, and we found that macrophages, their rate of phagocytosis depends on PIEZO, so that if you have too little PIEZO, they don't phagocytosis as much. If you have too much PIEZO, the phagocytosis too much. And this increased rate of phagocytosis in the long term because it's constantly eating red blood cells and the iron is circulating more causes long-term effects in iron overload. And again, as you kind of set that up, who would've thought that mechanical sensation is important for this basic hematology type?Eric Topol (25:52):Yeah, I mean, because we've been talking about the macro things, and here it is at the cellular level. I mean, it's just wild.Ardem Patapoutian (25:59):If you go back and look at a video of a macrophage eating up red blood cells, then you go, oh, I see how this has to do with pressure sensing because it is like extending little arms, feeling things letting go, going somewhere else. So again, I want to bring it back by this simple cell biological function of a cell type, like macrophage, exploring its environment is not just chemical, but very mechanical as well. And so, in retrospect, it is maybe not that surprising, that pressure sensing is important for its physiology.Career Changing?Eric Topol (26:33):Yeah, that's extraordinary. Well, that gets me to how your life has changed since 2021, because obviously this a big effect, big impact sort of thing. And I know that you're the first Armenian, first person from Lebanon to get this recognition. You recognized by the Lebanese Order of Merit. There's even a stamp of you, your picture characterized in 2022.Eric Topol (27:04):So if you were to sum up how it's changed because I see no change in you. You're the same person that has a great sense of humor. Often the tries to humor relaxed, calming. You haven't changed any to me, but how has it affected you?Ardem Patapoutian (27:26):Thank you, Eric. That's very kind of you. I try very hard for it not to change me. I do get a little bit more attention, a ton more invites, which unfortunately I have to say no to a lot of them because, and I'm sure you're very familiar with that concept and a lot of things are offered to you that I feel like it's so tempting to say yes because they're wonderful opportunities and an honor to be asked. But the end of the day, I'm trying to be very disciplined and not taking things on that I can do as an opportunity. But things that I really want to do. I think that's so hard to do sometimes is to separate those two. Why am I doing this? Is this really important for the goals that I have? So in one way, the answer for that is that I just want to stay in the lab and do my research with my students and postdoc, which is what I enjoy the most. But on the other hand, as you said, being the first Armenian who's received this, literally after the Nobel, I got this whole elementary school, all Armenian kids write to me multiple letters.Ardem Patapoutian (28:39):And they said, you look like me. I didn't think I could do this, but maybe I can. So in a sense, to ignore that and say, no, I just want to do my science, I don't want to be involved in any of that is also wrong. So I'm trying to balance being engaged in science outreach and helping to make science understood by the general public, realize that we're just regular people and at the same time how awesome science is. I love science and I like to project that, but leave plenty of time for me to just be a scientist and be in my lab and interact with my colleagues at Scripps, including you.Immigrant ScientistsEric Topol (29:21):Well, we're so lucky to have that chance. And I do want to mention, because you're prototyping in this regard about great immigrant scientists and other domains of course, but every year the Carnegie Foundation names these great immigrants and one year you were of course recognized. And in recent years, there have been more difficulties in people wanting to come to the US to get into science, and they wind up going to other places. It seems like that's a big loss for us. I mean, what if we weren't able to have had you come and so many hundreds, thousands of others that have contributed to this life science community? Maybe you could comment about that.Ardem Patapoutian (30:10):Yeah, I think it is tragic, as you say. I think in some circles, immigrants have this negative image or idea of what they bring, but at every level, immigrants have contributed so much to this country. It's a country of immigrants, of course, to start with. And I think it is important to put up a positive image of immigration and science is the ultimate example of that, right? I mean, I think when you go into any laboratory, you probably find if there's a lab of 16 people, you probably find people from 10 different countries. And we all work together. And the idea of also immigrant and especially about science is that I'm a big believer of changing field, changing things because just like that, immigrants have changed their whole life. So they come to a new culture, they bring with them their own way of thinking and their way of seeing things. And then you come into a new environment, and you see it a little bit differently. So that kind of change, whether it's because of physical immigration or immigrating from one field to another in science is really beneficial for science and society. And I think positive examples of this are an important part of highlighting this.Eric Topol (31:40):I couldn't agree with you more really.Bluesky vs Twitter/XEric Topol (31:41):Now, speaking of migration, there's been recently a big migration out of X, formerly Twitter to Bluesky, which I like the metaphor you liken to the Serengeti. Can you tell us about, now I know you're posting on Bluesky and of course so many others that you and I are mutual contacts, and our different networks are. What do you think about this migration outside of what was the platform where a lot of this, we shared things on X or before Musk took over known as Twitter? Thoughts about Bluesky?Ardem Patapoutian (32:27):Yeah, I think I use social media for a few reasons. The number one reason should be is to see new science by colleagues. My main point is that, but also, again, having fun in science is a big part of my draw to this. And as you can see from my posts, it's a bit lighthearted, and that's really me.Eric Topol (32:52):Right. Yeah.Ardem Patapoutian (32:52):I think on Twitter, things start getting a little bit dark and too many negative comments, and it was just not productive. And I just felt like after the elections, I felt like it was time to migrate. And I find Bluesky a great scientific community, and it's remarkable how quickly people have migrated from Twitter to Bluesky. But the counter argument for this is that you should stay in a place where majority of people are, because being in a bubble surrounding yourself by people like you doesn't help society. And so, I get that perspective as well. It just depends on what you're using the platform for and it's a difficult issue. But yeah, I've taken a break probably long-term break from Twitter. I'm on Bluesky now.Eric Topol (33:48):Yeah, no, the point you're bringing up about the echo chamber and is there going to be one for people that are leaning one way and they're thinking, and another with a whole different, often politically charged and even extreme views? It's really unfortunate if it does wind up that way. But right now, it seems like that migration is ongoing and it's substantial. And I guess we'll see how it settles out. I share your concern, and so far, I've been trying to keep a foot in both areas because I think if we all were to leave, then we're just kind of caving into a, it's tricky though. It really is because the noxious toxic type of comments, even when you try to avoid comments, you say, only followers can make a comment, they'll of course, quote your thing and then try to ding you and whatever. It's just crazy stuff, really.Ardem Patapoutian (34:53):I mean, what I think is that, that's why I said depends on why. I mean, your presence on social media is such an important part of science education. And I could almost say you can't afford to do what I do, which is I'm just putting my goofy posts and having fun. So we have different purposes in a way, and yeah, that affects what you use and how you use it.Eric Topol (35:17):Yeah, no, it's tricky it really is. We covered a lot of ground. Is there anything I missed that you want to get out there? Any part of this, your story and the PIEZO story, science and everything else that I didn't bring up?The Essentiality of Basic ScienceArdem Patapoutian (35:42):I just think that the basic science community is really suffering from decreasing amounts of funding and appreciation of doing basic science. And one of my goals, in addition to this immigrant scientist thing, is to remind people that all medicines start with basic science work. And funding this has mainly been through NIH and it's getting harder and harder for basic scientists to secure funding and I'm really worried about this. And we need to find ways to be okay for people to do basic science. And I'll give you one example. Whenever we make a publication and there's a journalist talking to us or some kind of press coverage, they ask, how is this directly affecting patients? And my work actually is very much related to patients, and I answer that question, but I also say, but it's also important to do science for the science sake because you don't know where the applications are going to come from. And we need to, as a society, encourage and fund and support basic science as the seeds of all these translational work. And I think doing that just kind of highlights that this is important too. We should support it, not just things that right now seem very related to translational that directly helps patients.Eric Topol (37:16):Well, I'm so glad you emphasized that because I mean, the PIEZO story is the exemplar. Look what's come of it, what might still come of it. In many respects here you are maybe 15 years into the story and there's still many parts of this that are untold, but if it wasn't for the basic science, we wouldn't have these remarkable and diverse insights. And recently you cited, and I think so many people read about the ‘crown jewel' NIH, front page New York Times, and how it's under threat because the new NIH director doesn't have a regard for basic science. He's actually, he's confirmed, which is likely, he's an economist, physician economist, never practiced medicine, but he doesn't really have a lot of regard for basic science. But as you point out, almost every drug that we have today came out of NIH basic work. And I mean, not just that, but all the disease insights and treatments and so much.Eric Topol (38:25):So this is really unfortunate if we have not just an NIH and other supporting foundations that don't see the priority, the fundamental aspect of basic science to then lead to, as we call translational, and then ultimately the way to promote human health, which is I think what we're all very much focused on ultimately. But you can't do it without getting to first base, and that's what you have done. You served it up and it's a great example. Well, Ardem, it's always a pleasure. This is a first time talking through a podcast. I hope we'll have many, many visits informally that will complement the ones we've already had, and we will follow the PIEZO work. Obviously, you have had just an exceptional impact, but you're still young and who knows what's next, right? I mean, look what happened to Barry Sharpless. He won here. He won two Nobel prizes, so you never know where things are headed.Ardem Patapoutian (39:36):Thank you, Eric, and I really appreciate what you do for the biomedical community. I think it's wonderful through your social media and this podcast, we all appreciate it.***********************************************************************************Please take a moment to complete the poll above.Thank you for reading, listening and subscribing to Ground Truths.If you found this informative please share it!All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and of course appreciated. All proceeds from them go to support Scripps Research. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. I welcome all comments from paid subscribers and will do my best to respond to each of them and any questions.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio and video support at Scripps Research.And Happy New Year! Get full access to Ground Truths at erictopol.substack.com/subscribe

How can policymakers make choices when confronted with uncertainty? What happens when the public loses confidence in scientific authority? Are scientists, including economists, overconfident? Nobel Laureate and UChicago economist Lars Hansen, a leading authority on uncertainty in economic decision-making, tackles these and related questions in this Extra Slice of The Pie, hosted by BFI Executive Director, Ben Krause. The answers will surprise you.

Jon Hartley and Myron Scholes discuss Myron's career, including being at the University of Chicago at the dawn of financial economics as a field, how Myron met Fischer Black, and the development of the Black-Scholes option pricing model, investing, innovation, and financial regulation. ABOUT THE SPEAKERS: Myron Scholes is the Frank E. Buck Professor of Finance, Emeritus, at the Stanford Graduate School of Business, Nobel Laureate in Economic Sciences, and co-originator of the Black-Scholes options pricing model. Scholes was awarded the Nobel Prize in 1997 for his new method of determining the value of derivatives. Scholes is currently the chairman of the board of economic advisers of Stamos Partners. Previously, he served as the chairman of Platinum Grove Asset Management and on the Dimensional Fund Advisors board of directors, American Century Mutual Fund board of directors, and the Cutwater advisory board. He was a principal and limited partner at Long-Term Capital Management, L.P., and a managing director at Salomon Brothers. Other positions Scholes held include the Edward Eagle Brown Professor of Finance at the University of Chicago, senior research fellow at the Hoover Institution, director of the Center for Research in Security Prices, and professor of Finance at MIT's Sloan School of Management. Scholes earned his PhD at the University of Chicago. Jon Hartley is the host of the Capitalism and Freedom in the 21st Century Podcast at the Hoover Institution and an economics PhD Candidate at Stanford University, where he specializes in finance, labor economics, and macroeconomics. He is also currently an Affiliated Scholar at the Mercatus Center, a Senior Fellow at the Foundation for Research on Equal Opportunity (FREOPP), and a Senior Fellow at the Macdonald-Laurier Institute. Jon is also a member of the Canadian Group of Economists, and serves as chair of the Economic Club of Miami. Jon has previously worked at Goldman Sachs Asset Management as well as in various policy roles at the World Bank, IMF, Committee on Capital Markets Regulation, US Congress Joint Economic Committee, the Federal Reserve Bank of New York, the Federal Reserve Bank of Chicago, and the Bank of Canada.  Jon has also been a regular economics contributor for National Review Online, Forbes, and The Huffington Post and has contributed to The Wall Street Journal, The New York Times, USA Today, Globe and Mail, National Post, and Toronto Star among other outlets. Jon has also appeared on CNBC, Fox Business, Fox News, Bloomberg, and NBC, and was named to the 2017 Forbes 30 Under 30 Law & Policy list, the 2017 Wharton 40 Under 40 list, and was previously a World Economic Forum Global Shaper. ABOUT THE SERIES: Each episode of Capitalism and Freedom in the 21st Century, a video podcast series and the official podcast of the Hoover Economic Policy Working Group, focuses on getting into the weeds of economics, finance, and public policy on important current topics through one-on-one interviews. Host Jon Hartley asks guests about their main ideas and contributions to academic research and policy. The podcast is titled after Milton Friedman‘s famous 1962 bestselling book Capitalism and Freedom, which after 60 years, remains prescient from its focus on various topics which are now at the forefront of economic debates, such as monetary policy and inflation, fiscal policy, occupational licensing, education vouchers, income share agreements, the distribution of income, and negative income taxes, among many other topics. For more information, visit: capitalismandfreedom.substack.com/

News: Idaho ruling @2:18 SCOTUS to review WI ruling @5:10 Politics: 75 Nobel Laureates @7:10 You can too @9:25 Here's why @11:20 McConnel warning @12:05 Groceries @16:39 Indigenous Knowledge @216: Pseudoscience: Telepathic transmitter tested…the results may surprise you! @24:54 Religious Nonsense: Kern County CA @30:14 Health/Medicine/Science: Master of the SLAP @32:02 Tejocote @34:57 UK expands block @38:30 Conspiracies: Project Blue Beam @41:35 Final Stories: Webb confirms faster expansion @44:53

TODAY ON THE ROBERT SCOTT BELL SHOW: Quantum Leap Into Health Orlando, Nobel Laureates Questions, Reiki Cancer Relief, Poor Health Longevity, mRNA Pre-eclampsia, Mygale Lasiodora, Liver Drug Warning, Ultraprocessed Foods Lawsuit, PFAS in Water, Texas Chemical Lawsuit, Friday the 13th and MORE! https://robertscottbell.com/quantum-leap-into-health-orlando-nobel-laureates-questions-reiki-cancer-relief-poor-health-longevity-mrna-pre-eclampsia-mygale-lasiodora-liver-drug-warning-ultraprocessed-foods-lawsuit-pfas-in/

TODAY ON THE ROBERT SCOTT BELL SHOW: Nobel Laureates Oppose RFK Jr, High-Fructose Corn Cancer, Carrageenan's Health Risks, FDA Certifies Banned Additives, Medusa Homeopathy, Tonsil Removal Stress, Air Toxins & School Disabilities, Bird Flu warning, Raw Milk Propaganda, Climate Change shocker and MORE! https://robertscottbell.com/nobel-laureates-oppose-rfk-jr-high-fructose-corn-cancer-carrageenans-health-risks-fda-certifies-banned-additives-medusa-homeopathy-tonsil-removal-stress-air-toxins-school-disabilities

Nobel prize laureates are pushing back against President-elect Donald Trump's choice to lead the Department of Health and Human Services. In a letter from earlier this week, the group asked Senators to oppose Robert F. Kennedy Jr.'s confirmation to the job. They say he would “put the public's health in jeopardy and undermine America's global leadership in the health sciences.”Kennedy has promoted conspiracy theories including one that pushes that COVID-19 was created to target certain racial groups and give other groups immunity. He has also denied the link between HIV and AIDS, a scientific discovery that has helped to treat and prevent AIDS around the world. Kennedy has also embraced the debunked theory that childhood vaccines cause autism. Dr. Brian Kobilka, a 2012 Nobel Laureate in chemistry is one of the scientists trying to prevent Kennedy from being confirmed as leader of the Department of Health and Human Services. Kobilka is originally from Little Falls and attended the University of Minnesota Duluth. He's now a professor at Stanford University and joined Minnesota Now to talk about his concerns.

This week Denton starts out on a happy note informing you of which states will be incinerated if we get hit by nukes. Then, the new reason to clutch your pearls...Trump's 3rd term! There are 77 Nobel Laureates that say you have to agree with them on EVERYTHING because they're smarter than you. BLM, what have you done for me lately? A couple of Karen's ruin a hundreds of years old festival (thanks Karen!). Also Denton explains sleep is good for you, who knew!?! And we round things off with some Weird News. 

Interview recorded - 22nd of November, 2024On this episode of the WTFinance podcast I had the pleasure of welcoming on Bjorn Lomborg. Bjorn is a renowned researcher and writer, currently president of the think tank Copenhagen Consensus Center, which researches the most effective solutions to the world's greatest challenges, from disease and hunger to climate and education. The findings of the 12 most efficient solutions for the world's poorest are laid out in his recently released book “Best Things First”.During our conversation we spoke about the UN's Sustainable Development Goals, whether they're pragmatic, why the current trajectory is off, what $35bn annually could to to benefit the world, value of life, best ways to reduce emissions and more. I hope you enjoy!0:00 - Introduction2:12 - Are UN SDG's realistic?6:42 - Shift away from pragmatism?7:50 - Influence for writing the book?10:18 - $35bn to add $1trn of value to developed economies?18:05 - Financial assumptions22:47 - Issues with current development aid27:38 - Value of life32:03 - Didn't hit the cut as too expensive?37:03 - Best way to reduce emissions?42:34 - One message to takeaway?Dr. Bjorn Lomborg is an academic and the author of the best-selling "False Alarm: How Climate Change Panic Costs Us Trillions, Hurts the Poor, and Fails to Fix the Planet", "The Skeptical Environmentalist" and "Cool It". He challenges mainstream concerns about development and the environment and points out that we need to focus attention on the smartest solutions first. He is a visiting fellow at the Stanford University's Hoover Institution, and president of the Copenhagen Consensus Center which brings together many of the world's top economists, including seven Nobel Laureates, to set priorities for the world. The University of Pennsylvania asked almost 7,000 think tanks and thousands of journalists, public and private donors, and policymakers from around the world to nominate and rank the world's best think tanks. Copenhagen Consensus Center's advocacy for data-driven smart solutions to global challenges were voted into the top 20 among NGOs with up to 100 times' larger budget. The Economist said “Copenhagen Consensus is an outstanding, visionary idea and deserves global coverage.”Lomborg is a frequent participant in public debates on policy issues. His analysis and commentaries have appeared regularly in such prestigious publications as the New York Times, Wall Street Journal, USA Today, The Economist, Washington Post, Forbes Magazine, Globe & Mail, The Guardian, The Daily and Sunday Telegraph, The Times, The Australian, Los Angeles Times, Boston Globe and Der Spiegel. Lomborg's monthly column appears in multiple languages in influential newspapers across all continents. He is a television commentator on CNN, FOX, MSNBC and the BBC, among others, on shows such as “Newsnight”, “20/20”, “60 Minutes”, “The Late Show with David Letterman”, and “Larry King Live”. He was featured in the movie “Cool It”, by Sundance Award winning director Ondi Timoner.Bjorn Lomborg - Book - https://www.amazon.co.uk/Audible-Best-Things-First/dp/B0CD8T9QDV/Website - https://lomborg.com/X - https://twitter.com/BjornLomborgWTFinance -Instagram - https://www.instagram.com/wtfinancee/Spotify - https://open.spotify.com/show/67rpmjG92PNBW0doLyPvfniTunes - https://podcasts.apple.com/us/podcast/wtfinance/id1554934665?uo=4Twitter - https://twitter.com/AnthonyFatseas

If they wanted only to hold you, the queens could hold you prisoner in this tribute to America's most recent Nobel Laureate. Please Support Breaking Form!Review the show on Apple Podcasts here.Pretty Please.....Buy our books:     Aaron's STOP LYING is available from the Pitt Poetry Series.     James's ROMANTIC COMEDY is available from Four Way Books.SHOW NOTES:"Happiness" from Descending FigurePart 9 of "Marathon" in Meadowlands "Adult Grief" in The Triumph of Achilles"Lost Love" in Ararat"New World" in Ararat"Averno" from Averno "Winter Morning" in Triumph of Achilles"Crossroads" in A Village LifeHere are some remembrances of Glück published in The Paris Review.Another terrific tribute appeared in Los Angeles Review of Books, collecting memories by Paul Tran, Katie Peterson, Spencer Reese, Eliza Gonzalez, and Richie Hofmann.Listen to Glück read "Crossroads."

In this episode of FYI, ARK Chief Investment Strategist Dr. Charles Roberts and ARK Analyst Nemo Despot, PhD speak with David Baker, Nobel Prize-winning scientist and pioneer in protein engineering. Baker shares insights into his revolutionary work on Rosetta and the evolution of AI-driven protein design tools. With advances in technologies like RoseTTAFold and generative AI, he discusses how the field is moving towards designing proteins that can neutralize pathogens, catalyze chemical reactions, and potentially combat neurodegenerative diseases. Charlie and Nemo also examine the implications for healthcare, aging, and drug discovery as Baker envisions a future where synthetic biology and AI enable groundbreaking therapeutic options.Key Points From This Episode:Introduction of David Baker and his achievements in protein design and engineering.RoseTTAFold's evolution and its role in advancing protein structure prediction.How protein design could impact healthcare and the development of new therapies.The use of generative AI and diffusion models in protein design for medical applications.Challenges of modeling protein function and dynamics with current AI models.Potential of AI-designed proteins in applications like cancer therapy and neurodegenerative diseases.The role of multiomic research in understanding causality and improving drug efficacy.The implications of synthetic molecular machines for nanotechnology.Integrating computational and experimental methods in protein engineering.Future directions for protein design in therapeutic development, including custom protein-based solutions for disease.

Please join my mailing list here

Americans nowadays don’t agree on much, but most have one thing in common: disappointment in their government and the direction of the country. According to University of Chicago Professor James Robinson, who jointly won the Nobel Prize in Economics this year, a lot of this discontentment can be tied back to economic inequality and a perception that economic gains of the past few decades haven’t substantially improved normal people’s lives. Plus, an update on Boeing as striking machinists reject the company’s latest offer in ongoing labor negotiations.

Americans nowadays don’t agree on much, but most have one thing in common: disappointment in their government and the direction of the country. According to University of Chicago Professor James Robinson, who jointly won the Nobel Prize in Economics this year, a lot of this discontentment can be tied back to economic inequality and a perception that economic gains of the past few decades haven’t substantially improved normal people’s lives. Plus, an update on Boeing as striking machinists reject the company’s latest offer in ongoing labor negotiations.

Since Daron Acemoglu just won the 2024 Nobel Memorial Prize in Economic Sciences alongside MIT Sloan professor Simon Johnson and University of Chicago professor James Robinson, we're revisiting  this powerful episode featuring Acemoglu's insights from 2023. In his groundbreaking book Power and Progress, Acemoglu exposes how the elite have weaponized technology to tighten their grip on wealth and influence, and explains how we can ensure that technological progress works for everyone, not just the wealthy few. This episode originally aired on August 22, 2023. Daron Acemoglu is the Institute Professor of Economics at MIT, the university's highest faculty honor, and a 2024 Nobel laureate. For the last twenty-five years, he has been researching the historical origins of prosperity, poverty, and the effects of new technologies on economic growth, employment, and inequality. He is an author (with James Robinson) of The Narrow Corridor and the New York Times bestseller Why Nations Fail. Twitter: @NarrowCorridor Further reading:  Trio of professors win Nobel economics prize for work on post-colonial wealth Democracy is in a ‘tough stretch.' New Nobel winners explain how to strengthen it Power and Progress: Our Thousand-Year Struggle Over Technology and Prosperity The Narrow Corridor: States, Societies, and the Fate of Liberty Website: http://pitchforkeconomics.com Twitter: @PitchforkEcon, @NickHanauer, @civicaction Instagram: @pitchforkeconomics Threads: pitchforkeconomics YouTube: @pitchforkeconomics Substack: The Pitch

Daron Acemoglu was just awarded the 2024 Nobel Prize in economics. Earlier this year, he and Steve talked about his groundbreaking research on what makes countries succeed or fail. SOURCES:Daron Acemoglu, professor of economics at the Massachusetts Institute of Technology. RESOURCES:The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel 2024.Power and Progress: Our Thousand-Year Struggle Over Technology and Prosperity, by Daron Acemoglu and Simon Johnson (2023)."Economists Pin More Blame on Tech for Rising Inequality," by Steve Lohr (The New York Times, 2022)."America's Slow-Motion Wage Crisis: Four Decades of Slow and Unequal Growth," by John Schmitt, Elise Gould, and Josh Bivens (Economic Policy Institute, 2018)."A Machine That Made Stockings Helped Kick Off the Industrial Revolution," by Sarah Laskow (Atlas Obscura, 2017)."The Long-Term Jobs Killer Is Not China. It's Automation," by Claire Cain Miller (The New York Times, 2016).Why Nations Fail: The Origins of Power, Prosperity, and Poverty, by Daron Acemoglu and James A. Robinson (2012)."The Colonial Origins of Comparative Development: An Empirical Investigation," by Daron Acemoglu, Simon Johnson, and James A. Robinson (American Economic Review, 2001)."Learning about Others' Actions and the Investment Accelerator," by Daron Acemoglu (The Economic Journal, 1993)."A Friedman Doctrine — The Social Responsibility of Business Is to Increase Its Profits," by Milton Friedman (The New York Times, 1970). EXTRAS:"What's Impacting American Workers?" by People I (Mostly) Admire (2024)."'My God, This Is a Transformative Power,'" by People I (Mostly) Admire (2023)."New Technologies Always Scare Us. Is A.I. Any Different?" by Freakonomics Radio (2023)."How to Prevent Another Great Depression," by Freakonomics Radio (2020)."Is Income Inequality Inevitable?" by Freakonomics Radio (2017).

On Big Brains, we get to speak to a lot of groundbreaking scholars and experts, but some conversations we walk away knowing we've just heard from someone who is really changing the world. We certainly felt that way years ago after talking to University of Chicago scholar James Robinson, and it turns out…the Nobel Prize committee agreed in 2024 when it awarded him a share of the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel.Robinson was honored for the exact work that we talked to him about nearly five years ago. The author of numerous best-selling books, including Why Nations Fail (2012) and The Narrow Corridor (2019), he won the Nobel this year because his work researching what makes nations succeed and…what makes them fail. There's no better time to refamiliarize ourselves with his important research and celebrate his Nobel win.

Today, we're talking about the newest Nobel Laureates; JPMorgan's optimistic economic outlook; Hurricane Milton cleanup beginning; and other top news for Monday, October 14th. Stay informed while remaining focused on Christ with The Pour Over Today. Please support our TPO sponsors! Cru: give.cru.org/tpo Upside: https://links.thepourover.org/Upside The Bible Study: https://links.thepourover.org/TheBibleStudy Politics for People Who Hate Politics: https://links.thepourover.org/PoliticsForPeopleWhoHatePolitics Keola Fit: https://links.thepourover.org/KeolaFit_Pod Compelled Podcast: https://links.thepourover.org/Compelled Dwell Differently: https://links.thepourover.org/DwellDifferently Nothing Left Unsaid Podcast: https://linktr.ee/tgnlu CCCU: https://www.mycccu.com/tpobonus Courage for Life Study Bibles: links.thepourover.org/CFL_Podcast_0901 Grace Bible for Kids: https://links.thepourover.org/GraceBibleforKids The Daily Walk Bible: https://links.thepourover.org/DailyWalk

F.A. Hayek's contributions to economics are hard to overstate. This week marks fifty years since Hayek became a Nobel Laureate for that work. Economists Peter Boettke and Bruce Caldwell detail some of Hayek's enduring contributions. Hosted on Acast. See acast.com/privacy for more information.

Does life exist beyond Earth, or is our planet genuinely unique? Can we recreate the origins of life in a lab? And what role does Mars play in the quest for cosmic life? I had the extraordinary honor of discussing this with two outstanding scientists, Mario Livio and Jack Szostak. Mario and Jack just released their new book, Is Earth Exceptional?, which seeks to answer whether life is a freak accident or a chemical inevitability. Tune in and join us for this mesmerizing exploration! Mario Livio is an astrophysicist and author known for his work in cosmology and his popular science books. Livio has significantly contributed to our understanding of dark energy, black holes, and other cosmic phenomena.  Jack Szostak is a prominent biologist and Nobel Laureate known for his significant contributions to understanding life's fundamental processes. He was awarded the Nobel Prize in Physiology or Medicine in 2009, along with Elizabeth Blackburn and Carol Greider, for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Key Takeaways: 00:00:00 Intro 00:01:33 “Life existing only on Earth is arrogant.” 00:04:09 Miller–Urey experiment 00:08:35 Does extraordinary evidence exist? 00:10:12 Judging a book by its cover 00:14:11 The origin of life  00:22:18 Thoughts on Rare Earth by Ward and Brownlee 00:24:59 The role of magnetite in the origin of life  00:31:30 Life on Mars?  00:55:15 Drake equation  00:58:54 Outro  Additional resources: ➡️ Learn more about Mario Livio: